CA
NZ
UK
AU
IND
US
…
Alcidion Group Limited, together with its subsidiaries, develops and sells digital health software solutions for healthcare organisations in Australia, New Zealand, and the United Kingdom. It offers Miya Precision, a fast healthcare interoperability resource (FHIR) events platform that integrates digital patient care services, such as a clinical decision support system, electronic patient record (EPR), and patient administration systems (PAS). The company's platform also provides electronic patient flow journey boards; virtual care and remote patient management; integrated care system smart operations center; emergency department and specialized care; real-time data integration, FHIR-based interoperability, and predictive analytics; modern modular EPR; and streamlined clinical workflows, intelligent comms, and mobility solutions. In addition, the company offers Smartpage, a smartphone and web-based system for hospital communication and task management; and product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alcidion Group is an Australian health‑tech company providing clinical information and decision‑support software to hospitals and health systems to improve care coordination and clinician workflows. Long-term growth may be supported by healthcare digitalization, demand for real-time clinical intelligence and expansion of contract-based deployments in public health markets; investors may be attracted by its specialist focus and recurring institutional contracts.
Principal risks include competition from large EHR and IT vendors, reliance on a limited number of public‑sector contracts, execution risk when scaling internationally and exposure to healthcare regulation and patient‑data security.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | 1.32M | 0.32M | -8.70M | -4.74M | -3.91M |
| Net income | 2.29M | 1.65M | -8.42M | -3.62M | -4.41M |
| Selling general administrative | - | 1.09M | 28.27M | 28.30M | 22.39M |
| Selling and marketing expenses | - | 0.74M | 0.93M | 0.84M | 0.58M |
| Gross profit | 9.16M | 35.99M | 31.92M | 1.25M | 3.29M |
| Reconciled depreciation | - | - | 4.10M | 3.19M | 2.26M |
| Ebit | - | -0.56M | -8.60M | -4.62M | -3.84M |
| Ebitda | 2.55M | 1.94M | -4.50M | -1.43M | -1.58M |
| Depreciation and amortization | - | 2.50M | 4.10M | 3.19M | 2.26M |
| Operating income | 2.55M | 7.81M | -7.65M | -4.73M | -1.73M |
| Other operating expenses | 49.09M | 32.98M | 44.70M | 45.13M | 36.08M |
| Interest expense | 0.06M | 1.00M | 0.10M | 0.12M | 0.07M |
| Tax provision | - | -1.33M | -0.28M | -1.12M | 0.50M |
| Interest income | - | - | 0.08M | 0.11M | 0.02M |
| Net interest income | - | - | -0.02M | -0.01M | -0.04M |
| Income tax expense | -0.97M | 1.33M | -0.28M | -1.12M | 0.50M |
| Total revenue | 51.64M | 40.79M | 37.06M | 40.40M | 34.35M |
| Total operating expenses | 6.61M | 28.18M | 31.26M | 5.98M | 5.02M |
| Cost of revenue | 42.48M | 4.80M | 5.14M | 39.15M | 31.06M |
| Total other income expense net | -1.24M | -7.49M | -1.05M | -0.01M | -2.18M |
| Net income from continuing ops | - | - | -8.42M | -3.62M | -4.41M |
| Net income applicable to common shares | - | 1.65M | -8.42M | -3.62M | -4.41M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 121.88M | 115.63M | 114.46M | 120.68M | 128.35M |
| Intangible assets | 22.37M | 22.59M | - | 29.07M | 31.06M |
| Other current assets | 3.02M | 2.31M | 1.53M | 1.60M | 1.67M |
| Total liab | 31.01M | 27.82M | 27.52M | 30.52M | 34.40M |
| Total stockholder equity | 90.87M | 87.80M | 86.94M | 90.17M | 93.95M |
| Other current liab | 21.65M | 19.54M | 5.38M | 6.84M | 9.22M |
| Common stock | - | 115.52M | 115.52M | 110.51M | 110.51M |
| Capital stock | - | - | - | 110.51M | 110.51M |
| Retained earnings | -26.08M | -28.37M | -30.02M | -21.60M | -17.99M |
| Other liab | - | - | - | 7.78M | 8.14M |
| Good will | - | 67.76M | 67.76M | 67.76M | 67.76M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 20.64M | 17.70M | 11.80M | 14.64M | 17.34M |
| Total current liabilities | 24.44M | 20.86M | 19.21M | 21.27M | 24.39M |
| Current deferred revenue | - | - | 12.83M | 11.61M | 12.91M |
| Net debt | -19.83M | -16.29M | -10.10M | -12.49M | -14.86M |
| Short term debt | 0.53M | 0.71M | 0.70M | 0.69M | 0.62M |
| Short long term debt total | 0.81M | 1.41M | 1.70M | 2.15M | 2.48M |
| Other stockholder equity | 116.95M | - | - | 0.32M | 1.43M |
| Property plant equipment | - | - | - | 2.87M | 3.27M |
| Total current assets | 29.72M | 23.69M | 18.54M | 20.98M | 26.26M |
| Net tangible assets | - | - | - | -6.67M | -4.87M |
| Net receivables | 6.06M | 3.68M | 5.21M | 4.74M | 7.25M |
| Accounts payable | 2.26M | 0.62M | 0.30M | 2.13M | 1.65M |
| Accumulated other comprehensive income | - | 0.65M | 1.45M | 1.26M | 1.43M |
| Non currrent assets other | - | - | 26.19M | - | -0.00M |
| Non current assets total | 92.16M | 91.94M | 95.92M | 99.71M | 102.09M |
| Capital lease obligations | - | - | - | 2.15M | 2.48M |
| Long term debt total | - | - | - | 1.46M | 1.87M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | -0.05M | -3.14M | -59.74M |
| Change to liabilities | - | - | - | -1.71M | 4.27M |
| Total cashflows from investing activities | -1.70M | -0.12M | -0.05M | -3.14M | -59.74M |
| Net borrowings | - | - | - | -0.62M | -0.61M |
| Total cash from financing activities | -0.80M | -0.76M | 4.34M | -0.62M | 51.33M |
| Change to operating activities | - | - | - | 0.54M | -0.53M |
| Net income | 2.29M | 1.65M | -8.42M | -3.62M | -4.41M |
| Change in cash | 2.94M | 5.90M | -2.84M | -2.70M | -7.69M |
| Begin period cash flow | 17.70M | 11.80M | 14.64M | 17.34M | 25.03M |
| End period cash flow | 20.64M | 17.70M | 11.80M | 14.64M | 17.34M |
| Total cash from operating activities | 6.85M | 5.76M | -7.13M | 0.17M | -2.16M |
| Issuance of capital stock | - | - | 5.40M | - | 51.94M |
| Depreciation | - | 4.59M | 4.10M | 1.81M | 2.26M |
| Other cashflows from investing activities | - | - | 0.00M | -2.69M | -59.43M |
| Change to account receivables | - | 0.80M | -0.48M | 2.52M | -1.30M |
| Sale purchase of stock | - | 0.00M | -0.40M | 0.00M | 51.94M |
| Other cashflows from financing activities | -0.80M | 0.00M | -0.66M | -0.62M | -0.61M |
| Change to netincome | - | - | - | -0.37M | 0.33M |
| Capital expenditures | 0.23M | 0.12M | 0.05M | 0.45M | 0.31M |
| Change in working capital | -1.57M | 0.63M | -1.06M | 0.11M | 0.02M |
| Stock based compensation | - | 0.13M | 0.15M | - | - |
| Other non cash items | 6.13M | -1.25M | -1.90M | - | 2.16M |
| Free cash flow | 6.62M | 5.64M | -7.18M | -0.28M | -2.47M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALC Alcidion Group Ltd |
-0.01 8.70% |
0.10 | - | 1.15 | 3.01 | 1.56 | 2.92 | 19.12 |
| PME Pro Medicus Ltd |
-3.10 1.49% |
205.13 | 81.98 | 106.38 | 83.13 | 43.70 | 74.38 | 95.34 |
| 4DX 4DMEDICAL Ltd |
-0.13 5.39% |
2.28 | - | - | 205.57 | 8.53 | 170.03 | -7.29 |
| CGS Cogstate Ltd |
-0.09 2.66% |
3.29 | 33.80 | 27.86 | 9.59 | 6.95 | 6.35 | 19.27 |
| AYA ARTRYA Ltd |
- -% |
3.50 | - | - | 20505.14 | 7.00 | 16927.51 | 0.33 |
Alcidion Group Limited, together with its subsidiaries, develops and sells digital health software solutions for healthcare organisations in Australia, New Zealand, and the United Kingdom. It offers Miya Precision, a fast healthcare interoperability resource (FHIR) events platform that integrates digital patient care services, such as a clinical decision support system, electronic patient record (EPR), and patient administration systems (PAS). The company's platform also provides electronic patient flow journey boards; virtual care and remote patient management; integrated care system smart operations center; emergency department and specialized care; real-time data integration, FHIR-based interoperability, and predictive analytics; modern modular EPR; and streamlined clinical workflows, intelligent comms, and mobility solutions. In addition, the company offers Smartpage, a smartphone and web-based system for hospital communication and task management; and product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.
| Name | Title | Year Born |
|---|---|---|
| Ms. Kate Quirke | MD, CEO & Exec. Director | NA |
| Mr. Matthew Gepp | Chief Financial Officer | NA |
| Mr. Colin Bruce MacKinnon | Chief Operating Officer | NA |
| Mr. Vivek Krishnan | Chief Technology Officer | NA |
| Kerstin Wahlqvist | Investor Relations Mang. | NA |
| Ms. Maria Hunter | Group Gen. Counsel | NA |
| Ms. Tracey Harvey | HR Mang. | NA |
| Ms. Lynette Ousby | UK Managing Director | NA |
| Ms. Amanda James | Chief People Officer | NA |
| Ms. Julia Stevens | Chief of Staff | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...